Advertisement
Advertisement

VVOS

VVOS logo

Vivos Therapeutics, Inc. Common Stock

0.44
USD
Sponsored
-0.02
-5.34%
Jun 24, 15:58 UTC -4
Closed
exchange

Pre-Market

0.46

+0.02
+3.53%

VVOS Earnings Reports

Positive Surprise Ratio

VVOS beat 8 of 21 last estimates.

38%

Next Report

Date of Next Report
Aug 17, 2026
Estimate for Q2 26 (Revenue/ EPS)
$5.60M
/
-$0.31
Implied change from Q1 26 (Revenue/ EPS)
+8.96%
/
-40.38%
Implied change from Q2 25 (Revenue/ EPS)
+46.64%
/
-43.64%

Vivos Therapeutics, Inc. Common Stock earnings per share and revenue

On May 20, 2026, VVOS reported earnings of -0.52 USD per share (EPS) for Q1 26, missing the estimate of -0.46 USD, resulting in a -12.46% surprise. Revenue reached 5.14 million, compared to an expected 4.31 million, with a 19.29% difference. The market reacted with a -0.88% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.31 USD, with revenue projected to reach 5.60 million USD, implying an decrease of -40.38% EPS, and increase of 8.96% in Revenue from the last quarter.
FAQ
For Q1 2026, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.52, missing estimates by -12.46%, and revenue of $5.14M, 19.29% above expectations.
The stock price moved down -0.88%, changed from $0.59 before the earnings release to $0.58 the day after.
The next earning report is scheduled for Aug 17, 2026.
Based on -- analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of $5.60M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement